Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies

被引:0
作者
Nicos, Marcin [1 ,2 ]
Wojas-Krawczyk, Kamila [1 ]
Krawczyk, Pawel [1 ]
Milanowski, Janusz [1 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, PL-20954 Lublin, Poland
[2] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2015年 / 24卷 / 04期
关键词
immunohistochemistry; genetic driver abnormalities; in situ hybridization; molecularly-targeted therapies; CELL LUNG-CANCER; GENE COPY NUMBER; BREAST-CANCER; EGFR EXPRESSION; GASTRIC-CANCER; PHASE-III; TRASTUZUMAB; AMPLIFICATION; DOCETAXEL; FISH;
D O I
10.17219/acem/28825
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Proper qualification of patients with cancer for an effective treatment regiment is essential to rationalize therapy benefit and costs. The early detection of genetic disorders that are responsible for the stimulation of uncontrolled cancer cells proliferation makes it possible to select a group of patients with a high probability of response to molecularly-targeted therapy. Data has shown that careful analysis of genes mutation using different PCR and sequencing techniques or chromosomal aberrations using in situ hybridization (ISH) techniques have a predictive value for drug targeted therapy. Overexpression of receptors and gene amplification has been reported in various cancers. Their detection is still a considerable challenge, which is connected with the unsatisfactory quality of DNA and low mutated cells percentage compared to cells with no genetic abnormalities in tested material. Different techniques of standardization were performed to prevent false negative results and to increase the sensitivity of qualitative and quantitative evaluation of chromosomal abnormalities. Immunohistochemistry (IHC) technique is useful in the screening of receptor expression in paraffin-embedded tissue samples in different malignant diseases. Whereas ISH techniques, especially fluorescence in situ hybridization (FISH), are now considered the diagnostic gold standard method in detection chromosomal aberrations. Moreover, molecular biology techniques, which are using molecular probes and real-time PCR and quantitative PCR techniques, were also applied for the detection of chromosomal changes. In order to identify the best genetic marker for treatment regiment, it is important to compare results of different studies, which are evaluating the sensitivity of diagnostic techniques and treatment response after a suitable selection factors based on genetic aberrations profile.
引用
收藏
页码:715 / 723
页数:9
相关论文
共 45 条
  • [1] EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
    Algars, A.
    Lintunen, M.
    Carpen, O.
    Ristamaki, R.
    Sundstrom, J.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (02) : 255 - 262
  • [2] [Anonymous], J CANC THERAPY, DOI DOI 10.4236/JCT.2011.25090
  • [3] [Anonymous], WORLD J GASTROENTERO
  • [4] Bang YJ, 2010, LANCET, V376, P1302
  • [5] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    Baselga, Jose
    Cortes, Javier
    Kim, Sung-Bae
    Im, Seock-Ah
    Hegg, Roberto
    Im, Young-Hyuck
    Roman, Laslo
    Pedrini, Jose Luiz
    Pienkowski, Tadeusz
    Knott, Adam
    Clark, Emma
    Benyunes, Mark C.
    Ross, Graham
    Swain, Sandra M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) : 109 - 119
  • [6] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
    Bergethon, Kristin
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    Katayama, Ryohei
    Lovly, Christine M.
    McDonald, Nerina T.
    Massion, Pierre P.
    Siwak-Tapp, Christina
    Gonzalez, Adriana
    Fang, Rong
    Mark, Eugene J.
    Batten, Julie M.
    Chen, Haiquan
    Wilner, Keith D.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Carbone, David P.
    Ji, Hongbin
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    Pao, William
    Iafrate, A. John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 863 - 870
  • [7] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
    Brugger, Wolfram
    Triller, Nadja
    Blasinska-Morawiec, Maria
    Curescu, Stefan
    Sakalauskas, Raimundas
    Manikhas, Georgy Moiseevich
    Mazieres, Julien
    Whittom, Renaud
    Ward, Carol
    Mayne, Karen
    Trunzer, Kerstin
    Cappuzzo, Federico
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4113 - 4120
  • [8] Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
    Campanella, Carla
    Mottolese, Marcella
    Cianciulli, Anna
    Torsello, Angela
    Merola, Roberta
    Sperduti, Isabella
    Melucci, Elisa
    Conti, Salvatore
    Diodoro, Maria Grazia
    Zeuli, Massimo
    Paoletti, Giancarlo
    Cognetti, Francesco
    Garufi, Carlo
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [9] Chen Tai-Di, 2012, Chang Gung Med J, V35, P309
  • [10] Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Cortes, Javier
    Fumoleau, Pierre
    Bianchi, Giulia Valeria
    Petrella, Teresa M.
    Gelmon, Karen
    Pivot, Xavier
    Verma, Shailendra
    Albanell, Joan
    Conte, Pierfranco
    Lluch, Ana
    Salvagni, Stefania
    Servent, Veronique
    Gianni, Luca
    Scaltriti, Maurizio
    Ross, Graham A.
    Dixon, Joanna
    Szado, Tania
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1594 - 1600